GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiMed Biologics Inc (ROCO:4147) » Definitions » Investments And Advances

TaiMed Biologics (ROCO:4147) Investments And Advances : NT$0.0 Mil (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is TaiMed Biologics Investments And Advances?

TaiMed Biologics's Investments And Advances for the quarter that ended in Mar. 2024 was NT$0.0 Mil.


TaiMed Biologics Investments And Advances Historical Data

The historical data trend for TaiMed Biologics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiMed Biologics Investments And Advances Chart

TaiMed Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TaiMed Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TaiMed Biologics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


TaiMed Biologics (ROCO:4147) Business Description

Traded in Other Exchanges
N/A
Address
No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a Taiwan-based biotechnology company. It is engaged in the discovery, development, and delivery of medicines for infectious disease. It capitalizes on its intellectual, extensive expertise, and management resources to develop a health-care product pipeline that benefits patients, rewards investors, and propels to prominence in the biotechnology industry. The company's products pipeline includes TMB-365, VRC07-523LS, and others.

TaiMed Biologics (ROCO:4147) Headlines

No Headlines